The abstract is read at the publisher; the summary is JClub's.
Intermittent dasatinib with a weekend holiday is noninferior to continuous 100 mg daily for major molecular remission at 24 months in first-line chronic phase chronic myeloid leukemia, with 81% vs 78%.
- Why it matters: Continuous dosing can limit tolerability, and the trial addresses whether a weekend drug holiday can maintain efficacy while improving patient outcomes in chronic phase chronic myeloid leukemia.
- What they did: In a prospective multicenter phase III randomized trial, patients with chronic phase chronic myeloid leukemia received either standard dasatinib 100 mg once daily or 5 days on/2 days off dosing, with major molecular remission at 24 months and a cumulative toxicity score as coprimary endpoints.
- The result: Grade 2–4 toxicities were similar, but pleural/pericardial effusion occurred in 16% (21/130) with continuous dosing versus 8% (10/125) with intermittent dosing (P = .0464), and quality of life improved mainly in first-line patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.